Abstract
In sheep infected with bovine leukemia virus (BLV), transcription of structural, enzymatic, and accessory genes is silenced. However, the BLV provirus transcribes a series of non-coding RNAs that remain undetected by the host immune response. Specifically, three RNAs (AS1-L, AS1-S, and AS2) are consistently expressed from the antisense strand, originating from transcriptional initiation at the 3’-Long Terminal Repeat (LTR). To investigate the role of these non-coding RNAs in viral replication and pathogenesis, a reverse genetics approach was devised, capitalizing on a mechanistic disparity in transcription initiation between the 5’ and 3’ promoters. A two-nucleotide mutation (GG>TA) in the TFIIB-recognition element (BRE) impaired antisense transcription originating from the 3’-LTR. In the context of the provirus, this 2bp mutation significantly diminished the expression of antisense RNAs, while not notably affecting sense transcription. When inoculated to sheep, the mutated provirus was infectious but exhibited reduced replication levels, shedding light on the role of antisense transcription in vivo. In comparison to lymphoid organs in sheep infected with a wild-type (WT) provirus, the mutant demonstrated alterations in both the spatial distribution and rates of cell proliferation in the lymph nodes and the spleen. Analysis through RNA sequencing and RT-qPCR unveiled an upregulation of the Hmcn1/hemicentin-1 gene in B-lymphocytes from sheep infected with the mutated provirus. Further examination via confocal microscopy and immunohistochemistry revealed an increase in the amount of hemicentin-1 protein encoded by Hmcn1 in peripheral blood mononuclear cells (PBMCs) and lymphoid organs of sheep infected with the mutant. RNA interference targeting Hmcn1 expression impacted the migration of ovine kidney (OVK) cells in vitro. In contrast to the WT, the mutated provirus showed reduced oncogenicity when inoculated into sheep. Collectively, this study underscores the essential role of antisense transcription in BLV replication and pathogenicity. These findings may offer valuable insights into understanding the relevance of antisense transcription in the context of human T-cell leukemia virus (HTLV-1).
Author summary
In sheep infected with bovine leukemia virus (BLV), the transcription of genes encoding viral proteins is silenced. However, the virus constitutively produces long non-coding RNAs from the opposite strand of the integrated genome. To comprehend their role, we used reverse genetics to alter the BLV sequence, reducing the production of these antisense RNAs. When inoculated to sheep, this modified virus was infectious but could not replicate as well. Compared to the original strain, the number of mutated viruses was reduced in the peripheral blood and the lymphoid organs. Gene expression in B-cells from sheep infected with the mutated virus was altered, particularly affecting the Hmcn1 gene, which is involved in cell migration. Importantly, the modified virus did not cause leukemia in sheep, indicating the involvement of antisense RNAs in effective cancer development. In summary, our study underscores the significance of these antisense RNAs in the ability of the virus to replicate and induce illness. This understanding may offer insights into similar mechanisms in viruses affecting humans such as HTLV-1.
Introduction
A series of species including cattle (Bos taurus), water buffalo (Bubalus bubalis), yak (Bos grunniens) and zebu (Bos taurus indicus) can be naturally infected with the bovine leukemia virus (BLV) [1–4]. In the bovine species, persistent infection by BLV leads to B-cell lymphoproliferative diseases: persistent lymphocytosis (PL) and leukemia/lymphoma (enzootic bovine leukosis, EBL) [2]. Persistent infection of bovines by BLV is associated with impaired immunity, weight loss and an overall decrease of productivity, which is detrimental to the dairy and meat industries [5,6]. While the implementation of eradication measures successfully resulted in a BLV-free status in European countries [7], EBL prevalence is rising to severe levels elsewhere [8–10]. Although culling of cattle having high proviral loads is possible, vaccination is likely the most effective strategy in regions characterized by a high prevalence [9,11]. Besides prevention, there is no therapeutic option that prevents disease onset, although administration of lysine deacetylase inhibitors effectively reduce proviral loads in vivo [12]. Understanding the mechanisms of BLV replication and pathogenesis is thus required to develop novel economically sustainable strategies. In a perspective of the one health concept, BLV infection has been correlated with human cancer, although convincing experimental evidence demonstrating a causal link is still lacking [13,14].
Besides the development of therapeutic and preventive strategies, the BLV model may be useful to better understand the human T-cell leukemia virus (HTLV-1). In a comparative virology approach, both related retroviruses indeed share several characteristics but infect different species. Unfortunately, the long latency period (7–10 years) and the low frequency of disease onset (5–10%) are major limitations of studies based on bovines naturally infected with BLV. However, BLV can also be experimentally inoculated to sheep, inducing almost invariably leukemia/lymphoma after a latency period of 2–3 years [15].
In this study, focus was given on a particular mechanism shared by BLV and HTLV-1: the ability of their long terminal repeats (LTRs) to initiate transcription in the sense and antisense orientations. Transcription directed by the 5’-LTR promoter generates the genomic viral RNA that also encodes the structural and enzymatic genes: gag (MA, NC and CA), pro (protease) and pol (reverse transcriptase and integrase). Alternative splicing further creates the transcript of env (SU and TM) as well as other RNAs including tax, rex, R3 and G4. Transcription from the antisense strand initiates from a promoter located in the 3’-LTR generating a series of viral RNAs (as1-L / as1-S / as2 in BLV and shbz / ushbz in HTLV-1) [16,17]. The role of the BLV antisense RNAs is still unknown but is predicted to affect epigenetic mechanisms due to the lack of a significant open reading frame and to their major nuclear localization [18]. In contrast, the antisense RNA of HTLV-1 encodes the HBZ protein (HTLV-1 bZIP factor) that has been much better characterized [19–21]. Notably, the HBZ polypeptide counteracts some functions exerted by Tax protein including activation of 5’-LTR-directed transcription and NFκB signaling [19,21,22]. In absence of translated protein, the hbz ribonucleic acid prevents the binding of the TATA-binding protein (TBP) to the 5’-LTR chromatin and represses transcription of sense RNAs [23].
Upon infection of a cell by a BLV virion, the process of reverse transcription of the genomic RNA produces identical copies of the 5’-LTR and 3’-LTR. After integration, the provirus can remain silent or be transcribed in both orientations from different promoters located in these terminal sequences. Sense transcription initiates in the U3 region of the 5’-LTR with the binding of TBP to the TATA box, which in turn recruits the RNA polymerase (RNAP) type II (RNAPII) (Fig 1A). Upstream of this transcriptional start site, three 21-base pairs (bp) Tax-responsive elements (TxRE) contain imperfectly conserved cyclic-AMP recognition element (CRE) that interact with the CRE-binding protein (CREB) and activation transcription factors 1/2 (ATF1/2) [24,25]. This complex further recruits the CREB-binding protein (CBP), that acetylates the surrounding chromatin. Although other cellular factors interact with the 5’-LTR, the major activator of sense transcription is the viral Tax protein [17]. The process of antisense transcription is initiated in the 3’-LTR at a TATA-less RNAPII core promoter containing a TFIIB-recognition element (BRE) and motif ten/downstream promoter elements (MTE/DPE) (Fig 1A). In this study, the mechanistic difference in 5’- and 3’-LTR promoter initiation was exploited to investigate the role of antisense transcription using a reverse genetics approach.
Results
A mutation of the BRE decreases antisense transcriptional activity of the LTR promoter
To understand the biological function of BLV antisense transcription, a reverse genetics approach was used to selectively target the antisense promoter located in the 3’-LTR (Fig 1A). Therefore, a series of mutations were introduced by site-directed mutagenesis in the BRE and MTE/DPE core elements located in the R-U5 region of the LTR as indicated on Fig 1B. The mutations were targeted to the 2 transcription initiation sites of antisense RNAs (A, A1 and A2 in the BRE and B in the MTE/DPE). The GG>TA and GC>TA mutations were designed to disrupt the interaction of the promoter element to the Transcription factor II B (TFIIB). The mutated LTR sequences were inserted into a reporter plasmid containing the Renilla and Firefly luciferase genes cloned in opposite orientations (Fig 1C). The different mutants were introduced in bidirectional reporter vectors containing the full-length LTR or a minimal promoter devoid of U3 (R-U5). Upon transfection of human embryonic kidney cells (HEK293FT) with the R-U5 reporter, no Firefly-luciferase activity could be detected above background levels indicating that sense transcription required U3, as expected (Fig 1D). Transfection of the R-U5 reporter produced Renilla-luciferase activity that was not significantly affected by the A2/B1 mutations (Fig 1E). In contrast, the GG to TA mutation present in the A/A1 reporters reduced Renilla-luciferase activity. A similar effect of the mutations was observed in the presence of the Tax transcriptional activator (pSGTax [26]). In the context of a full-length LTR, the A1 mutation slightly increased expression of Firefly-luciferase in basal conditions (pSG5) and after co-transfection of pSGTax (Fig 1F). Compared to the WT, Renilla-luciferase activity was significantly reduced by the A1 mutation in absence and presence of Tax (Fig 1G). The A1 mutation also reduced antisense transcription in reporter assays performed with the Ovine Kidney (OVK) cell line (S1 Data).
These dual luciferase reporter assays thus revealed that a minimal two-nucleotide mutation (A1) in the BRE affects antisense transcriptional activity directed by the LTR promoter.
A provirus carrying the A1 mutation transcribes less antisense RNAs, does not affect envelope-mediated cell fusion and is slightly more infectious in cell cultures
To evaluate the effect of antisense transcription in the proviral context, the A1 mutation was introduced in an infectious BLV molecular clone (pBLV344, Fig 2A). After transfection into HEK293FT, viral transcription, transmission to ovine cells and envelope-mediated cell fusion were analyzed by RT-qPCR, co-culture with OVK-U3Luc reporter cells and syncytia formation, respectively [27–29] (Fig 2B).
RT-qPCR quantification revealed that the levels of antisense RNAs were reduced in cells transfected with the A1 provirus compared to the WT control (p = 0.004; as1 by 5-fold and as2 by 11.9-fold; Fig 2C). In contrast, the WT and A1 viruses expressed similar amounts of Tax RNAs (p = 0.41), indicating that sense transcription remained mostly stable. To assess viral transmission, HEK293FT transfected with proviruses WT/A1 were then co-cultured with an ovine cell line transduced with a luciferase gene controlled by the U3 promoter (OVK-U3Luc). The luciferase activity increased by a factor of 1.7-fold (p = 0.03), suggesting that the A1 mutation may slightly improve viral infectivity (Fig 2D). However, the ability to promote cell fusion with CC81 indicator cells, as estimated by the number and the size of syncytia, was not statistically different (p = 0.55) (Fig 2E and 2F). The coculture of HEK293FT with CC81 cells did not significantly modify the transcriptional pattern of the WT and A1 proviruses (S2 Data).
These observations thus show that, compared to the WT, the A1 provirus transcribes significantly less antisense RNAs, is slightly more infectious and induces similar levels of cell fusion events in transient transfection experiments.
The A1 provirus is infectious in sheep but replicates at reduced proviral loads
To investigate the role of antisense transcription in vivo, sheep were inoculated with the WT proviral clone (n = 5) or the A1 mutant (n = 5). After 20 to 35 days, antibodies directed against the surface receptor-binding subunit of the viral envelope protein (gp51, SU) were detected in the plasma of all animals. The anti-gp51 reactivity was similar in sheep inoculated with the A1 and WT proviruses and persisted over time revealing the onset of an antiviral immune response (p = 0.64; Fig 3A). Quantitative PCR revealed that, compared to the WT, the proviral loads were reduced by 39-fold in the PBMCs of A1-infected sheep (p = 0.002; Fig 3B). The normalized RNA loads of as1-S/L and as2 evaluated by RT-qPCR were also significantly decreased in the A1 PBMCs (p = 0.004 and p = 0.04 respectively; Fig 3C). In contrast, the levels of the Tax transcripts in the two groups were variable but not statistically different (p = 0.91). To evaluate the expression of viral proteins, PBMCs were transiently cultured overnight and analyzed by confocal microscopy using a monoclonal antibody directed against the p24 capsid protein (Fig 3D). At the single cell level, the p24 mean fluorescence intensities (MFIs) were similar in PBMCs infected with WT and A1 viruses (p = 0.42; Fig 3E).
To characterize the mechanisms ongoing in sheep infected with the WT provirus and the A1 mutant, the transcriptome of their B lymphocytes was determined by RNA sequencing. After isolation of B-cells by magnetic-activated cell sorting (MACS), RNAs were purified, converted to cDNA and sequenced with an Illumina NovaSeq6000 device (Fig 3F). After quality control and trimming, the sequencing reads (100bp, 30M, paired-end) were aligned on the Ovis aries reference genome (Oar_rambouillet_v1.0) using the HISAT2 (version 2.2.1) software. After alignment and quantification using featureCounts, differentially expressed genes were identified between cell populations using DESEq2 Bioconductor package. The volcano plot highlighted specific changes (DEG at p-adj < 0.05 and |Log2FC| > 1) that correlated with infection with A1 and WT viruses (S3–S6 Data). Particularly, the Hmcn1 gene, coding for the hemicentin-1 protein, was highly upregulated (p-adj = 5.29*10−127 and |Log2FC| = 7.46; red arrow on Fig 3G). The heatmap of the 30 most significant DEG highlighted significant differences in the transcriptome of A1 and WT-infected B-cells (Fig 3H). To obtain a comprehensive view of the underlying mechanisms, an unsupervised analysis of the transcriptomic data set was performed. Gene Ontology (GO) comparison and pathway enrichment analysis revealed that KEGG pathways pertaining notably to proliferation (oas04110 “Cell cycle”, oas04110 “DNA replication”), signal transduction (oas04015, “Rap1 signaling pathway”, oas04060 “cytokine-cytokine receptor interaction”) and adhesion (oas04514 “cell adhesion molecule”, oas04510 “focal adhesion”) were the most significantly affected (Fig 3I). In contrast, the transcriptome was almost similar in the non-B cells from A1- and WT-infected sheep (S3, S7–S9 Data). Sashimi plots drawn by Integrative Genomics Viewer (IGV) confirmed that RNA loads were reduced in A1 PBMCs compared to WT but could not reveal any significant alteration of splicing events (S10 Data).
Altogether, these results reveal that the A1 mutant replicates at reduced proviral loads and deeply modifies the transcriptome of infected B-cells.
Hemicentin-1 is upregulated in PBMCs and secondary lymphoid organs of A1-infected sheep
Among the DEGs identified by RNA sequencing, the expression of Hmcn1 appeared to be particularly high in B-lymphocytes of A1-infected sheep compared to the WT and mock controls (NI) (Fig 3). To validate this observation independently, RT-qPCR showed that the normalized fold-change of Hmcn1 RNA in A1-infected sheep exceeded that in NI and WT by 538 and 810-fold, respectively (p<0.0001; Fig 4A). Confocal microscopy further demonstrated that the expression of the hemicentin-1 protein encoded by the Hmcn1 gene increased in A1-infected PBMCs and p24+ cells compared to the WT (Fig 4B, 4C and 4D).
Hemicentin-1 (Fibulin-6 or ARMD1) is a member of the immunoglobulin superfamily that is expressed in a wide range of tissues including lymphoid conduits [30,31]. Hemicentin-1 mediates a wide range of mechanisms such as cytoskeleton rearrangements, mitosis [32,33], basement membrane invasion [30,34–36] and cell migration [37,38]. To investigate the role of hemicentin-1, OVK cells were transduced with lentivectors encoding Hmcn1 shRNAs (sh1, sh2) or a scrambled (scrbl) control. Effective RNA interference of Hmcn1 transcription was demonstrated by RT-qPCR (2.5-fold by sh1 and 3-fold by sh2; Fig 4E). The motility of shRNA-transduced OVK cells was then recorded for 48 hours by Incucyte live-cell imaging. Migration of individual cells was measured using the QuPath software and graphed using MatLab (Fig 4F). As hypothesized, knock-down of Hmcn1 reduced the ability of OVK cells to undergo cell migration (p = 0.001 and p<0.001 for sh1 and sh2, respectively; Fig 4G).
To extend these observations, the expression of hemicentin-1 was determined by immunohistochemistry in lymphoid organs from WT- and A1-infected sheep. Hemicentin-1 was expressed in the spleen and lymph node of an A1-infected animal (Fig 4H and 4I). In contrast, hemicentin-1 could not be detected in a biopsy of a prescapular lymph node isolated from a WT-infected sheep (Fig 4I). Expression of hemicentin-1 was significantly higher in the spleen of A1-infected sheep compared to the wild-type (n = 7.21 and n = 1.68 hemicentin-1+ cells / mm2 in A1 and WT biopsies, respectively). Confocal microscopy revealed that hemicentin-1 predominantly aggregated in the intercellular space within lymphoid organs (Fig 4J and S11 Data).
Extending the RNA sequencing data (Fig 3), it appears that a factor regulating cell migration, the hemicentin-1 protein, is overexpressed in PBMCs and in lymphoid organs from sheep infected by the A1 mutant.
The A1 mutation attenuates oncogenesis in sheep
The pathogenesis induced by BLV is tightly controlled by the immune response mediated by lymphoid organs. In particular, cell proliferation in the spleen has a central role in virus-driven leukemogenesis [39,40]. To evaluate proliferation, Ki67-based immunochemistry was performed on biopsies of lymphoid organs. Compared to WT, the number of Ki67+ cells was moderately reduced by 1.73-fold in the lymph nodes of sheep infected with the A1 mutant (p<0.0001; Fig 5A). In contrast, cell proliferation in the A1 spleen increased by a factor of 9 compared to WT (p<0.0001; Fig 5B). The number of proviral copies per μg of genomic DNA determined by qPCR dropped by 54.3- and 197.8-fold in the lymph node and the spleen of A1-infected sheep (p = 0.002; Fig 5C and 5D). When normalized to the total viral load, the spatial distribution of the A1 proviruses in the PBMCs and the lymphoid organs was affected. Compared to WT, the relative proportion of A1 proviral DNA was reduced by 4.3-fold in the spleen (Fig 5E). In contrast, the percentages of A1 and WT proviral DNA were proportionally similar in the lymph nodes (1.9% and 1.2%, respectively). In other terms, attenuated replication of the A1 mutant correlated with increased cell proliferation and reduced spatial distribution of the proviruses in the spleen.
The five sheep inoculated with either the WT provirus or the A1 mutant remained persistently infected as indicated by the continuous presence of plasmatic antiviral antibodies (Fig 5F). The PVLs were significantly lower in the A1-infected sheep than in the WTs (p = 0.0001; Fig 5G). While the WT provirus was pathogenic, none of the A1-infected sheep developed any clinical manifestation of leukemia or lymphoma (S12 Data). Quantitative PCR and sequencing revealed that the two-nucleotide mutation introduced in the BRE of the A1 proviruses did not revert to WT (illustrated for #0582 in Fig 5H).
Collectively, these data thus show that the A1 mutant replicates at reduced proviral loads and attenuates pathogenicity in sheep.
Discussion
The main take home message of this study is that antisense transcription is involved in BLV persistence and pathogenesis in sheep. The outcomes of this fundamental research for management of bovine leukemia/lymphoma are unclear but may be informative to better understand the mechanisms associated with the pathogenesis of HTLV-1. Indeed, the relevance of the animal models developed to characterize HTLV-1-associated diseases is sometimes questionable. Transgenic mice have been useful to demonstrate the oncogenic potency of viral genes such as Tax and HBZ [41,42]. Since these models are independent of viral replication, rabbits and humanized mice may provide a better overview but fail to recapitulate a fully competent immune response [43]. The same questions addressed in different models may also generate contradictory conclusions [44]. Among primates, cynomolgous and rhesus macaques [45,46] have been very useful models but are inadequate to study HTLV-1 associated pathogenesis because of the low frequency of leukemia and the long latency period. To complement the conclusions drawn from these different models, a comparative virology approach of BLV-infected sheep may thus broaden the understanding of retroviral-induced oncogenesis.
In the present report, the relevance of antisense transcription has been tackled by a reverse genetics approach. This strategy has been useful to highlight the relevance of genetic determinants involved in infectivity, replication and oncogenicity [25,28,47]. The intrinsic drawback of reverse genetics is that a targeted mutation may affect several functional elements because of the complexity of a condensed and relatively small BLV genome (~ 8.7 Kbp) [48,49]. In particular, a major difficulty of addressing antisense transcription is that mutations in one strand would also have affected the other. Our strategy to investigate the relevance of antisense transcription has been based on mutations introduced in the LTRs flanking the BLV genome. Although the two-nucleotide mutation in the BRE is limited, it cannot be excluded that other mechanisms are also affected. What is worthy of note, however, is that the mutation in the BRE does not overlap the rex-responsive element that mediates post-transcriptional regulation of viral gene expression [50,51]. Since the process of reverse transcription duplicates the two terminal sequences, a mutation of the 3’ antisense promoter is copied into the 5’-LTR promoter. In reporter assays using a single LTR flanked by Firefly and Renilla luciferase genes, sense transcription appears to be increased by the A1 mutation in HEK293FT but not in OVK cells (Fig 1F and S1 Data), revealing cell type specificities. Since the increase of sense transcription was observed neither in the context of a full-length provirus (Fig 2C) nor in vivo (Fig 3A–3E), it appears that the A1 molecular clone optimally fulfils the different characteristics required to address the role of antisense transcription.
Why is replication of the A1 mutant affected in sheep? Among hypotheses, the collisions between RNA polymerases transcribing opposite DNA strands may be reduced and favor the expression of structural/enzymatic genes thereby exposing the virus to the host immunity. Similarly, mutations of the Tax-response elements that optimize the CRE elements increase promoter activity but interfere with viral replication in sheep [25]. As indicated in the former paragraph, we think that this paradigm is unlikely because (1) transcription of tax RNA from A1 and WT proviruses is similar (Fig 2C), (2) there is only a modest increment in infectivity (Fig 2D), (3) there is no significant difference in cell fusion (Fig 2F) and (4) the expression of p24 protein is identical at the single cell level in vivo (Fig 3E). Since sense transcription is mostly unaffected, it is also unlikely that the A1 mutation reduces steric hindrance of the polymerase complex at the 5’-LTR. Notwithstanding that the A1 mutation does not overlap the polypurine tract (PPT) and the primer binding site (PBS) (S13 Data), it is predicted that the process of reverse transcription of the A1 provirus is also similar to WT. Other hypotheses that may explain the reduced replication of A1 more directly involve an epigenetic role of the antisense RNA as demonstrated for HTLV-1 [23], the activity of a putative small peptide encoded by 264bp open reading frame (ORF) [52] or cis-perturbation of cancer driver genes in the host genome [53].
Whatever the molecular mechanism, it appeared that the expression of Hmcn1/hemicentin-1 was particularly high in A1-infected cells as shown by RNA sequencing (Fig 3), RT-qPCR (Fig 4A), confocal microscopy of PBMCs (Fig 4B–4D), and immunochemistry of lymphoid tissues (Fig 4H–4J). As mentioned above, antisense RNAs may modulate Hmcn1 expression by epigenetic modifications [23], or alternatively via transcription factors such as cFos known to mediate HMCN1 promoter activity [54,55]. However, luciferase-based reporter assays with a plasmid controlled by sequences overlapping the Hmcn1 promoter did not reveal significant difference after transfection of A1 and WT proviruses (S14 Data). suggesting an indirect mechanism ongoing inside infected cells. Similarly, it is unclear why Hmcn1 expression is also increased to a lesser extent in the non-B cell population (S3 and S7 Data). Evidence indicating that Hmcn1/hemicentin-1 can be indirectly induced by cytokines (TGFβ), glucose and signaling pathways (MAPK) [55,56] needs to be specifically addressed by further experiments.
Although the role of hemicentin-1 in BLV persistence and replication is currently unknown, RNA interference shows that cell migration is affected (Fig 4E–4G). This phenotype is consistent with the involvement of hemicentin-1 in TGFβ-mediated cytoskeleton rearrangements, organization of F-actin fibers [55] and architecture of epithelial cell junctions. Importantly, hemicentin-1 also promotes cleavage furrow maturation during cytokinesis [33,35]. The expression of hemicentin-1 detected by immunohistochemistry (Fig 4H–4J) may thus indirectly reflect cell mitosis and proliferation, as previously observed in B and non-B cells infected with a provirus lacking the miRNAs (see S1 Table of reference [57]). It thus appears that alterations of hemicentin-1 expression likely affect important mechanisms such as cell migration or mitosis. Therefore, an overall hypothesis may be summed up as follows: through an indirect mechanism, the lack of antisense RNAs increases the production of hemicentin-1 protein, which accumulates mostly as tracks in the extracellular space of lymphoid organs. These tracks may affect leukocyte trafficking ultimately resulting in a better control of the proviral load and oncogenesis.
Addressing antisense transcription by reverse genetics in the ovine model reveals an essential role exerted by the lymphoid organs. This experimental evidence extends previous observations showing that splenectomy accelerates pathogenesis in sheep suggesting that the spleen is required for antiviral immunity [58]. Homeostasis is preserved providing an equilibrium between cell proliferation and death in lymphoid organs and peripheral blood. For example, the deletion of the viral microRNAs from the BLV genome (i.e., mutant ΔmiRNA [57]) leads to a reduction of proliferation both in lymph nodes as well as in spleen. In vivo kinetic studies based on CFSE and BrdU labeling revealed a concomitant reduced proliferation in the peripheral blood of sheep infected with the ΔmiRNA deletant. Cell dynamics that characterize the A1 mutant are different because proliferation is reduced in the lymph node but increased in the spleen (Fig 5). It thus appears that unevenness associated with the kinetics of the ΔmiRNA and A1 mutants leads to attenuation of their pathogenic activity.
Because the A1 proviral loads in the lymphoid organs is extremely low (Fig 5C and 5D), the high rates of cell proliferation revealed by the KI67 labelling (Fig 5A and 5B) mostly correspond to uninfected cells. It is thus likely that these cells are T-lymphocytes that are activated by antiviral immunity. As supported by many previous reports, BLV infection is associated with an increase in T cell proliferation as a marker of an active antiviral immune response [59,60]. Experiments based on intravenous injection of CFSE and BrdU would precisely quantify the cell kinetics in vivo [40,57,58]. In BLV-infected sheep, antiviral immunity is centrally controlled by the spleen because splenectomy accelerates the onset of leukemia/lymphoma [58]. On the other side, provirus-carrying B cells undergo active proliferation to persist, accumulate and ultimately induce leukemia in sheep [61]. Similarly, the HTLV-1 induced Adult T-cell leukemia/lymphoma (ATLL) and HTLV-associated myelopathy / tropical spastic paraparesis (HAM/TSP) are also characterized by active proliferation of provirus-carrying cells [62]. This interpretation is consistent with the mostly accepted paradigm of a virus that attempts to replicate in presence of a vigorous antiviral immunity. This model postulates that the virus undergoes cycles of transcriptional silencing and transient burst of expression allowing infection of new cells. Challenging these cycles with epigenetic activators leads to a reduction of the proviral loads and has therapeutic value in BLV-infected sheep [12,63,64].
Does the present report open perspectives for therapy of BLV-induced leukemia/lymphoma? Currently, management of EBL aims at preventing viral prevalence in herds by genetic selection based on specific DRB3 alleles [65,66], selective eradication of animals with high PVL [9] and vaccination [11]. Because of economical constraints, therapy of EBL is not considered and, therefore, interfering with antisense transcription of BLV is not an adequate option. For the related HTLV-1 however, the use of shRNA interference or peptide nucleic acids targeting hbz may be useful to reduce viral replication. Alternatively, disequilibrate the balance between sense and antisense transcription for example with pharmacological inhibitors, epigenetic modifiers and perhaps hemicentin-1 inducers may have therapeutic value [46,67–70]. Clinical trials are required to address the effectiveness and safety of these different approaches against HTLV-1.
Materials and methods
Ethics statement
Animal experimentation was conducted in accordance with national (Royal Decree on the Protection of Experimental Animals) and international (European Union) guidelines. Sheep were kept under L2-restricted conditions (registration number LA1900600), according to the ethical protocols n°1515/2067, approved by the Commission d’éthique de l’utilisation des animaux à l’université de Liège (Uliège), at the Centre d’Etude en Production Animales (CEPA) facility located in Gembloux (Belgium).
Plasmid constructions
The full-length LTR (531bp) and the R-U5 fragment (last 132bp) of the pBLV344 provirus [71] were inserted into the KpnI and PstI restriction sites of the dual luciferase reporter plasmid pAsLuc(Fire)-HTLV-Luc(Reni) [72] using standard molecular biology techniques. In these pAsLuc(Fire)-531bp-Luc(Reni) and pAsLuc(Fire)-132bp-Luc(Reni) constructs, the HTLV LTR was thus replaced by BLV sequences. Mutations (A, A1, A2 and B1) were introduced in these reporter vectors using the XL QuickChange II Site-Directed Mutagenesis kit (Agilent Technologies) and primers listed in S15 Data. Mutation A1 was also introduced in both LTRs of plasmid pBLV344 containing a full-length wild-type provirus [71], yielding pBLV344-A1.
The pU3BLV-Luc lentivector (Vector ID VB201221-1032xzh; VectorBuilder) contains the 79bp BLV enhancer element [73], cloned upstream of the pGL3Basic minimal promoter and the humanized Luc2 Firefly luciferase gene. Lentivectors coding for short hairpin RNA against Hmcn1 (shRNA1 5’-AGCGATAAAGGGACATATATT-3’ and shRNA2 5’-CAAAGATGGCAAGCCTTTATT-3’) were obtained from VectorBuilder (Vector ID VB220127-1038fqz and vector ID VB220127-1040mmq, respectively). The scrambled control (GVV_659 pLV shRNA NT) was provided by Emmanuel Di Valentin (GIGA viral vector platform). The packaging plasmids pSPAX2 (#12260) and VSV.G (#14888) were obtained from Addgene.
Cell culture and lentiviral transduction
Human embryonic kidney cells (HEK293FT; Cellosaurus CVCL_6911) and OVK [28] were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Biowest) supplemented with 10% decomplemented fetal bovine serum (FBS, Gibco) and 1% of penicillin-streptomycin solution 100x (VWR). The CC81 feline cell line [29] (Cellosaurus CVCL_7216) was cultured in Roswell Park Memorial Institute 1640 medium (RPMI 1640, Biowest) supplemented with 10% decomplemented FBS and 1% of penicillin-streptomycin solution. All cultures were maintained at 37°C, in a humidified 95–5% air/CO2 incubator (Memmert ICO150).
The OVK-U3Luc, OVK-shRNA1, OVK-shRNA2 and OVK-Scramble cell lines were generated by lentiviral transduction of the OVK cell line. Lentivectors (429 ng) encoding scrambled/sh1/sh2 shRNAs and pU3BLV-Luc were co-transfected in HEK293FT (2.5x105 cells/well of a 6-well plate) with VSV.G (857 ng) and pSPAX2 (1.714 μg) using Jetprime (Westburg). Supernatant (2 mL) of transfected HEK293FT cells was harvested 72 hours post-transfection, filtered through 0.45 μm cellulose membrane filters and added to OVK (5x105) in presence of hexadimethrine bromide (3.66 μg/mL; Sigma-Aldrich). At 72 hours post-transduction, antibiotic selection was performed for two weeks with blasticidin (20 μg/mL; InvivoGen).
Dual-luciferase assays
The WT and mutated bidirectional reporters (50 ng pAsLuc(Fire)-531bp-Luc(Reni) and pAsLuc(Fire)-132bp-Luc(Reni) were cotransfected with 300 ng of a plasmid encoding Tax (pSGTax [26]) or a control (pSG5) into HEK293FT cells (5x105 cells/well of a 6-well plate) using Jetprime reagent. Cells were lysed at 24 hours post-transfection and Renilla/Firefly luciferase activities were measured with a luminometer (Turner Designs TD-20/20) using the Dual-Luciferase Reporter Assay system (Promega), according to the manufacturer’s protocol.
Syncytia formation
The pBLV344 and pBLV344-A1 plasmids (20 μg) were mixed with 21 μg of polyethyleneimine (25 kD, Polysciences) in OPTI-Minimum Essential Medium (OPTI-MEM, Gibco) and added to HEK293FT cells (2x106 cells in a 10 cm diameter culture plate) for 24 hours. After replacement of the medium, HEK293FT cells were cultured for 24 hours, washed with Dulbecco’s Phosphate Buffered Saline (DPBS, Biowest) and detached with trypsin-EDTA (Biowest). Transfected HEK293FT (3x105) cells were added to CC81 cells (1.5x106) in a 10 cm diameter culture plate. After 72 hours, cells were washed and stained in 5mL May-Grünwald buffer (Sigma-Aldrich) for 3 minutes at room temperature. After addition of 5mL of water for 1 minute, the stain was removed and replaced by 10 mL of 10% giemsa’s azue methylene blue solution (Merck) for 20 minutes. Finally, the stain was removed, and cells were washed with 10 mL of neutral water.
The number of syncytia with more than 10 nuclei were scored by two different operators using a inverted light microscope (Motic AE 2000). Representative pictures were taken with the Motic 3.0 live software.
In vitro infectivity assays
Plasmids pBLV344 and pBLV344-A1 (1 μg) were transfected using Jetprime into HEK293FT cells (5x105 cells/well of a 6-well plate). After replacement of the medium 24 hours post-transfection, cells were cultured for one day and mixed with OVK-U3Luc (5x105 cells/well of a 6-well plate). 24 hours later, Renilla and Firefly luciferase activities were measured with a luminometer using the Dual-Luciferase Reporter Assay system, according to the manufacturer’s protocol.
Live cell imaging
OVK-scramble, OVK-shRNA1 and OVK-shRNA2 cells (9x103 cells/well of a 96-well plate) were cultured at 37°C in a humidified 95/5% air/CO2 incubator of an Incucyte imaging S3 Live-cell system (Sartorius). Migration of individual cells was recorded every 15 minutes using the CellTracker software (v1.1) [74]. Each frame underwent vignetting correction by bicubic interpolation and frames were aligned prior to the analysis. Manual tracking of each individual cell was performed, with a linear interpolation between each frame. Motility graphs were generated using the MATLAB software (MathWorks).
Inoculation of proviruses into sheep
Plasmids pBLV344 or pBLV344-A1 (20 μg) were transfected into HEK293FT cells (9x106 cells in a 15 cm diameter culture plate), using 60 μL of polyethyleneimine (1 μg/μL, 25 kD, Polysciences) in 1 mL of OPTI-MEM. After overnight culture, cells were washed with DPBS and cultured in fresh medium for 24 hours. Transfected HEK293FT cells were detached with trypsin-EDTA, pelleted by centrifugation and resuspended in 1 mL DPBS. After a freeze-thaw cycle at -80°C, the cell lysate was inoculated intravenously and subcutaneously into sheep.
At regular time intervals, whole blood was collected by jugular venipuncture using 2% ethylenediaminetetraacetic acid (v/v) (EDTA, VWR) as anticlotting agent. After collecting the plasma, PBMCs were separated by Percoll (Merck) gradient centrifugation and preserved at -80°C in FBS containing 10% DMSO. The detection of anti-gp51 antibodies in the plasma was performed by ELISA (BLV gp51 Antibody Test Kit; IDEXX), according to the manufacturer’s protocol. Optical density at 450nm (OD450) was measured with a Multiskan GO Microplate Spectrophotometer (Thermo Fisher Scientific). The seropositivity score was calculated using the following formula: 100–100 multiplied by (OD450 of the sample to be tested divided by OD450 of the negative control). The sample was considered seropositive providing that the score was > 60%.
Proviral load quantification by qPCR
Genomic DNA was extracted from PBMCs using the Blood and Tissue kit (Qiagen), according to the manufacturer’s protocol. The PCR mix contained 2.5 μL of DNA at 20 ng/μL, 6.25 μL of TAKYON ROX master mix (Eurogentec), 0.25 μL of forward and reverse primers at 20 μM (S15 Data) and 3.25 μL of milliQ-grade water. Real-time PCR amplification was performed in a thermocycler (Stepone Real-Time PCR, Applied Biosystems). The thermal protocol was initiated by a 10 minutes denaturation step at 95°C, followed by 40 cycles (15 sec at 95°C, 60 sec at 60°C) and terminated by a melting curve (1 minute at 60°C, increasing 0.3°C steps every 15 sec up to 95°C). The number of viral copies was normalized to a standard curve performed with the 18S cellular gene (2*BLV/18S), as described previously [28,75]. The number of viral copies per cell was then obtained by multiplying the BLV/18S ratio by the average value of the number of 18S copies per cell. The spatial distribution of the virus was determined by comparing the calculated proviral copy number measured in 1μg of DNA extracted from PBMCs, spleen and lymph node to the total amount of proviral copies detected in these tissues.
RNA quantification by RT-qPCR
RNA was extracted from transfected cells and PBMCs using the NucleoSpin RNA kit (Macherey-Nagel) according to the manufacturer’s protocol. Total RNA (200 ng) was converted to cDNA with the Reverse Transcriptase core kit (Eurogentec). 2 μL of complementary DNA (cDNA) was amplified by qPCR, using the same thermocycling protocol as described above, using primers corresponding to hmcn1, actin and viral transcripts (as1, as2 and Tax; S15 Data). Relative quantification was performed using actin as housekeeping gene.
Sequencing of proviral amplicons
DNA was extracted from PBMCs using the DNeasy Blood and Tissue kit (Qiagen), according to the manufacturer’s protocol. Genomic DNA (500 ng) was amplified in a mix containing 1 μL forward and reverse primers (20 μM round 1; S15 Data), 0.25 μL Taq polymerase (500 U/μL, Thermo Scientific), 5 μL Taq buffer 10X (Thermo Scientific), 3 μL MgCl2 (25mM, Thermo Scientific), 1 μL dNTP mix (2 mM, Thermo Scientific) and 36.75 μL miliQ-grade water. The protocol of the thermocycler (Veriti 96-Well Thermal Cycler, Applied Biosystems) was initiated by a 5 minutes denaturation step at 95°C, followed by 40 cycles (30 sec at 95°C, 30 sec at 67°C, 1 minutes at 68°C) and terminated by 5 minutes at 68°C. A 2 μL aliquot of the PCR mix was reamplified with round 2 primers at an annealing temperature of 58°C. DNA amplicons were migrated onto a 1% agarose gel, purified using the QIAquick gel extraction kit (Qiagen) and sequenced by the GIGA genotranscriptomic platform. Chromatograms were analyzed using the Chromas software (Technelysium).
Immunohistochemistry of lymphoid organs
Spleen and lymph node biopsies were fixed in 4% paraformaldehyde (PFA, Sigma-Aldrich) for 24 hours and conserved in 70% ethanol (VWR). Biopsies were then embedded in paraffin, sectioned with a motorized microtome (Microm HM355S, Thermofischer Scientific / RM2165, Leica) and deposited onto glass slides. Deparaffinization and rehydration were performed by successive washes: xylene (VWR) (n = 3; 5 minutes), 100% ethanol (n = 2; 10 minutes), 95% ethanol (n = 2; 10 minutes) and distilled water (n = 2; 5 minutes). Antigen was retrieved in a pressure cooker (Ultra Cell Conditioning Solution, 950–224, Roche) in either EDTA (11 minutes, Invitrogen) or citrate buffer (15 minutes, Invitrogen). After cooling for 30 minutes, slides were washed three times with Tris-buffered saline with Tween 20 (TBST) (pH 7.4) under gentle agitation and incubated one hour at room temperature with a blocking solution (TBST-FBS 10%). Slides were washed in distilled water and incubated with primary antibodies against Ki67 (Ventana 790–4286) or hemicentin-1 (18837-1-AP, ProteinTech) overnight in a humidified chamber at 4°C. Slides were washed 4x 5 minutes with TBST under gentle agitation and incubated with secondary antibodies (anti-mouse IgG AlexaFluor 488 (Invitrogen) or anti-rabbit IgG AlexaFluor 647 (Invitrogen), respectively). After 3 TBST washes for 5 minutes under gentle agitation, the nuclei were labelled with DAPI (2μM, 422801, Biolegend) for 15 minutes in the dark. Immunostaining was revealed using the HIGHDEF red IHC chromogen (AP) (Enzo Life Science), and imaged with a Microscope Slide Scanner (ZEISS Axioscan). For confocal microscopy, slides were washed 3x 5 minutes with TBST under gentle agitation, fixed with 8 μL of Prolong Glass Antifade Montant (ThermoFisher), and recorded with a Leica Stellaris device. All images were analyzed using the QuPath-0.3.0 software [76].
Confocal microscopy and flow cytometry analysis of PBMCs
After venipuncture, PBMCs were purified by Percoll gradient centrifugation and cultured in RPMI 1640 (Lonza) supplemented with 10% decomplemented FBS, 1% of penicillin-streptomycin solution, phorbol 12-myristate 13-acetate (PMA, 10ng/mL, Invivogen) and ionomycin (1 μg/mL, VWR) [25,77]. After fixation in 4% PFA and permeabilization with PBS-Triton X-100 0.5%, cells were labelled with antibodies directed against p24 (4’G9 monoclonal) and hemicentin-1. After staining with Draq5 (Invitrogen), samples were incubated with appropriate conjugates (anti-mouse IgG AlexaFluor 488 and anti-rabbit IgG AlexaFluor 647, respectively), mounted on slides using Fluoroshield (Sigma-Aldrich) and imaged with the Zeiss LSM 510 confocal microscope. Data was analyzed with the ZEN Blue software (Zeiss). For flow cytometry analyzes, cell events were recorded with a BD FACSAria (BD Biosciences) or a CytoFLEX (Beckman Coulter) cytometer. Data was analyzed using the BD FACS Diva (BD Biosciences), CytoFLEX (Beckman Coulter), FlowJow V10 and the CytExpert 2.5 softwares.
Transcriptomic analysis
After Percoll gradient centrifugation, 106 PBMCs were labelled with anti-sIgM antibody (monoclonal 1H4) and loaded onto a LS MACS column (Miltenyi Biotec) fixed on a QuadroMACS magnetic separator (Miltenyi Biotec). After collecting the flowthrough fraction (i.e., non-B cells) and washing the column with DPBS, the B cells were recovered. Total RNA was extracted from the B and non-B populations using the RNA Nucleospin extraction kit (Macherey-Nagel) according to the manufacturer’s protocol. After verifying with a bioanalyzer that the RNA Integrity Number (RIN) exceeded 7.0, poly-A libraries were generated with the Illumina TruSeq stranded mRNA kit (Illumina) and sequenced with a NovaSeq6000 sequencing device (Macrogen). At least 30 million 100 bp paired-end, reads were recorded corresponding to a sequencing coverage of approximately 46 using the Lander/Waterman equation. After quality check with FastQC, reads were aligned on the ovine reference genome (Oar_rambouillet_v1.0) using HISAT2 (version 2.2.1). The number of sequences that mapped to known genes were quantified with the featureCounts method from subread package (version 2.0.3). A Principal Components Analysis (PCA) was performed to exclude sample outliers. Differentially expressed genes were identified using DESEq2 (version 1.32.0). Volcano plots of top significant genes were generated using the EnhancedVolcano (version: 1.16.0) and ggplot2 (version 3.3.3) R packages. Chord diagrams were generated using GOplot (version:1.0.2) R package.
Statistics
All statistical analyses were performed using the GraphPad Prism 8.0.1 and the Microsoft Office 365 Suite softwares. For all tests, the threshold significance α was set at 0.05. Normality of distributions was tested according to the D’Agostino & Pearson test, using the method of Royston. Luciferase luminescence, number of syncytia, proviral loads, mean fluorescence intensity and number of positive cells in immunohistochemistry were compared between groups according to Mann-Whitney tests or unpaired t tests. Fold changes of RNA quantities were calculated according to two-tailed Wilcoxon signed rank test. Proviral load kinetics between WT and A1-infected animals were evaluated with Wilcoxon matched-pairs signed rank test. Kaplan-Meier survival curves were compared using the Log-rank Mantel-Cox test.
Supporting information
Acknowledgments
We appreciate the valuable help of the GIGA technology platforms, in particular the imaging, viral vectors, genotranscriptomic and immunohistology facilities. We would like to thank Sui Xiukun and Lin Li for their contribution on site-directed mutagenesis. The pAsLuc(Fire)-HTLV-Luc(Reni) plasmid was kindly provided by Benoît Barbeau.
Data Availability
RNA sequencing Data has been uploaded on GEO. The accession number is GSE255715.
Funding Statement
This work was supported by the Fonds de la Recherche Scientifique-FNRS grant numbers FNRS PDR T.O261.20, PER H.P055.20, CDR J.0195.21, and J.0194.23 to LW, Télévie grants 7460621 and 7460923 to LW, Université de Liège grant FSR-S-SS-2023/14 to LW, and Fonds Léon Fredericq to LW. The funders played no role in the design of the study, the collection and analysis of data, the decision to publish or the preparation of the manuscript.
References
- 1.Meas S., Usui T., Ohashi K., Sugimoto C. & Onuma M. Vertical transmission of bovine leukemia virus and bovine immunodeficiency virus in dairy cattle herds. Vet. Microbiol. 84, 275–282 (2002). doi: 10.1016/s0378-1135(01)00458-8 [DOI] [PubMed] [Google Scholar]
- 2.Burny A., Cleuter Y., Kettmann R., Mammerickx M., Marbaix G., Portetelle D. et al. Bovine leukaemia: facts and hypotheses derived from the study of an infectious cancer. Cancer Surv. 6, 139–159 (1987). [PubMed] [Google Scholar]
- 3.EFSA Panel on Animal Health and Welfare (AHAW), More S., Botner A., Butterworth A., Calistri P., Depner K. et al. Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): enzootic bovine leukosis (EBL). EFSA J. 15, (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Burny A., Bruck C., Cleuter Y., Couez D., Deschamps J., Ghysdael J. et al. Bovine leukemia virus, a versatile agent with various pathogenic effects in various animal species. Cancer Res. 45, 4578s–4582s (1985). [PubMed] [Google Scholar]
- 5.Nakada S., Fujimoto Y., Kohara J., Adachi Y. & Makita K. Estimation of economic loss by carcass weight reduction of Japanese dairy cows due to infection with bovine leukemia virus. Prev. Vet. Med. 198, 105528 (2022). doi: 10.1016/j.prevetmed.2021.105528 [DOI] [PubMed] [Google Scholar]
- 6.Nakada S., Fujimoto Y., Kohara J. & Makita K. Economic losses associated with mastitis due to bovine leukemia virus infection. J. Dairy Sci. 106, 576–588 (2023). doi: 10.3168/jds.2021-21722 [DOI] [PubMed] [Google Scholar]
- 7.Marawan M. A., Alouffi A., El Tekhy S., Badawy S., Shiani I., Dawood A., et al. Bovine Leukaemia Virus: Current Epidemiological Circumstance and Future Prospective. Viruses 13, 2167 (2021). doi: 10.3390/v13112167 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.LaDronka R. M., Ainsworth S., Melinda J. W., Norby B., Byrem T. M. & Bartlett P. C. Prevalence of Bovine Leukemia Virus Antibodies in US Dairy Cattle. Vet. Med. Int. 2018, 1–8 (2018). doi: 10.1155/2018/5831278 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Bartlett P. C., Ruggiero V. J., Hutchinson H. C., Droscha C. J., Norby B., Sporer K. R. B. et al. Current Developments in the Epidemiology and Control of Enzootic Bovine Leukosis as Caused by Bovine Leukemia Virus. Pathogens 9, 1058 (2020). doi: 10.3390/pathogens9121058 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Benitez O. J., Norby B., Bartlett P. C., Maeroff J. E. & Grooms D. L. Impact of bovine leukemia virus infection on beef cow longevity. Prev. Vet. Med. 181, 105055 (2020). doi: 10.1016/j.prevetmed.2020.105055 [DOI] [PubMed] [Google Scholar]
- 11.Suárez Archilla G., Gutiérrez G., Camussone C., Calvinho L., Abdala A., Alvarez I. et al. A safe and effective vaccine against bovine leukemia virus. Front. Immunol. 13, 980514 (2022). doi: 10.3389/fimmu.2022.980514 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Achachi A., Florins A., Gillet N., Debacq C., Urbain P., Manfouo Foutsop G., et al. Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. Proc. Natl. Acad. Sci. 102, 10309–10314 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Buehring G. C. & Sans H. M. Breast Cancer Gone Viral? Review of Possible Role of Bovine Leukemia Virus in Breast Cancer, and Related Opportunities for Cancer Prevention. Int. J. Environ. Res. Public. Health 17, 209 (2019). doi: 10.3390/ijerph17010209 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Gillet N. A. & Willems L. Whole genome sequencing of 51 breast cancers reveals that tumors are devoid of bovine leukemia virus DNA. Retrovirology 13, 75 (2016). doi: 10.1186/s12977-016-0308-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Olson C. & Baumgartener L. E. Pathology of lymphosarcoma in sheep induced with bovine leukemia virus. Cancer Res. 36, 2365–2373 (1976). [PubMed] [Google Scholar]
- 16.Joris T., Safari R., Jacques J.-R. & Willems L. Bovine Leukemia Virus (Retroviridae). in Encyclopedia of Virology 144–152 (2021). [Google Scholar]
- 17.Plant E., Bellefroid M. & Van Lint C. A complex network of transcription factors and epigenetic regulators involved in bovine leukemia virus transcriptional regulation. Retrovirology 20, 11 (2023). doi: 10.1186/s12977-023-00623-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Andoh K., Nishimori A. & Matsuura Y. The bovine leukemia virus-derived long non-coding RNA AS1-S binds to bovine hnRNPM and alters the interaction between hnRNPM and host mRNAs. Microbiol. Spectr. e00855–23 (2023). doi: 10.1128/spectrum.00855-23 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Ma G., Yasunaga J.-I. & Matsuoka M. Multifaceted functions and roles of HBZ in HTLV-1 pathogenesis. Retrovirology 13, 16 (2016). doi: 10.1186/s12977-016-0249-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Yoshida M., Satou Y., Yasunaga J.-I., Fujisawa J.-I. & Matsuoka M. Transcriptional control of spliced and unspliced human T-cell leukemia virus type 1 bZIP factor (HBZ) gene. J. Virol. 82, 9359–9368 (2008). doi: 10.1128/JVI.00242-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Toyoda K. & Matsuoka M. Functional and Pathogenic Roles of Retroviral Antisense Transcripts. Front. Immunol. 13, 875211 (2022). doi: 10.3389/fimmu.2022.875211 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Barbeau B., Peloponese J.-M. & Mesnard J.-M. Functional comparison of antisense proteins of HTLV-1 and HTLV-2 in viral pathogenesis. Front. Microbiol. 4, 226 (2013). doi: 10.3389/fmicb.2013.00226 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Gazon H. Chauhan P. S., Porquet F., Hoffmann G. B., Accolla R. & Willems L. Epigenetic silencing of HTLV-1 expression by the HBZ RNA through interference with the basal transcription machinery. Blood Adv. 4, 5574–5579 (2020). doi: 10.1182/bloodadvances.2020001675 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Adam E., Kerkhofs P., Mammerickx M., Burny A., Kettmann R. & Willems L. The CREB, ATF-1, and ATF-2 transcription factors from bovine leukemia virus-infected B lymphocytes activate viral expression. J. Virol. 70, 1990–1999 (1996). doi: 10.1128/JVI.70.3.1990-1999.1996 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Merezak C., Pierreux C., Adam E., Lemaigre F., Rousseau G. G., Calomme C. et al. Suboptimal Enhancer Sequences Are Required for Efficient Bovine Leukemia Virus Propagation In Vivo: Implications for Viral Latency. J. Virol. 75, 6977–6988 (2001). doi: 10.1128/JVI.75.15.6977-6988.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Chen G., Willems L., Portetelle D., Willard-Gallo K. E., Burny A., Gheysen D. et al. Synthesis of functional bovine leukemia virus (BLV) p34tax protein by recombinant baculoviruses. Virology 173, 343–347 (1989). doi: 10.1016/0042-6822(89)90254-7 [DOI] [PubMed] [Google Scholar]
- 27.Jaworski J. P., Pluta A., Rola-Luszczak M., McGowan S., Finnegan C., Heenemann K. et al. Interlaboratory Comparison of Six Real-Time PCR Assays for Detection of Bovine Leukemia Virus Proviral DNA. J. Clin. Microbiol. 56, e00304–18 (2018). doi: 10.1128/JCM.00304-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.de Brogniez A., Bouzar A.-B., Jacques J.-R., Cosse J.-P., Gillet N., Callebaut I. et al. Mutation of a Single Envelope N-Linked Glycosylation Site Enhances the Pathogenicity of Bovine Leukemia Virus. J. Virol. 89, 8945–8956 (2015). doi: 10.1128/JVI.00261-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Ferrer J. F., Cabradilla C. & Gupta P. Use of a feline cell line in the syncytia infectivity assay for the detection of bovine leukemia virus infection in cattle. Am. J. Vet. Res. 42, 9–14 (1981). [PubMed] [Google Scholar]
- 30.Lin M.-H., Pope B. D., Sasaki T., Keeley D. P., Sherwood D. R. & Miner J. H. Mammalian hemicentin 1 is assembled into tracks in the extracellular matrix of multiple tissues. Dev. Dyn. Off. Publ. Am. Assoc. Anat. 249, 775–788 (2020). doi: 10.1002/dvdy.159 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Fagerberg L., Hallström B. M., Oksvold P., Kampf C., Djureinovic D., Odeberd J. et al. Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics. Mol. Cell. Proteomics 13, 397–406 (2014). doi: 10.1074/mcp.M113.035600 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Xu X., MengMeng X., Zhou X., Jones O. B., Moharomd E., Pan Y., et al. Specific structure and unique function define the hemicentin. Cell Biosci. 3, 27 (2013). doi: 10.1186/2045-3701-3-27 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Xu X. & Vogel B. E. A secreted protein promotes cleavage furrow maturation during cytokinesis. Curr. Biol. CB 21, 114–119 (2011). doi: 10.1016/j.cub.2010.12.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Schultz D. W., Weleber R. G., Lawrence G., Barral S., Majewski J., Acott T. S. et al. HEMICENTIN-1 (FIBULIN-6) and the 1q31 AMD locus in the context of complex disease: review and perspective. Ophthalmic Genet. 26, 101–105 (2005). doi: 10.1080/13816810590968023 [DOI] [PubMed] [Google Scholar]
- 35.Welcker D., Stein C., Feitosa N. M., Armistead J., Zhang J.-L., Lütke S. et al. Hemicentin-1 is an essential extracellular matrix component of the dermal-epidermal and myotendinous junctions. Sci. Rep. 11, 17926 (2021). doi: 10.1038/s41598-021-96824-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Morrissey M. A., Keeley D. P., Hagedorn E. J., McClatchey S. T.H., Chi Q., Hall D. H. et al. B-LINK: a hemicentin, plakin, and integrin-dependent adhesion system that links tissues by connecting adjacent basement membranes. Dev. Cell 31, 319–331 (2014). doi: 10.1016/j.devcel.2014.08.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Vogel B. E. & Hedgecock E. M. Hemicentin, a conserved extracellular member of the immunoglobulin superfamily, organizes epithelial and other cell attachments into oriented line-shaped junctions. Dev. Camb. Engl. 128, 883–894 (2001). doi: 10.1242/dev.128.6.883 [DOI] [PubMed] [Google Scholar]
- 38.Chowdhury A., Herzog C., Hasselbach L., Khouzani H. L., Zhang J., Hammerschmidt M. et al. Expression of fibulin-6 in failing hearts and its role for cardiac fibroblast migration. Cardiovasc. Res. 103, 509–520 (2014). doi: 10.1093/cvr/cvu161 [DOI] [PubMed] [Google Scholar]
- 39.Debacq C., Gillet N., Asquith B., Sanchez-Alcaraz M. T., Florins A., Boxus M. et al. Peripheral Blood B-Cell Death Compensates for Excessive Proliferation in Lymphoid Tissues and Maintains Homeostasis in Bovine Leukemia Virus-InfectedSheep. J. Virol. 80, 9710–9719 (2006). doi: 10.1128/JVI.01022-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Florins A., Gillet N., Asquith B., Debacq C., Jean G., Schwartz-Cornil I. et al. Spleen-dependent turnover of CD11b peripheral blood B lymphocytes in bovine leukemia virus-infected sheep. J. Virol. 80, 11998–12008 (2006). doi: 10.1128/JVI.01447-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Nakajima S. & Okuma K. Mouse Models for HTLV-1 Infection and Adult T Cell Leukemia. Int. J. Mol. Sci. 24, 11737 (2023). doi: 10.3390/ijms241411737 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Satou Y., Yasunaga J.-i, Zhao T., Yoshida M., Miyazato P., Takai K. et al. HTLV-1 bZIP Factor Induces T-Cell Lymphoma and Systemic Inflammation In Vivo. PLoS Pathog. 7, e1001274 (2011). doi: 10.1371/journal.ppat.1001274 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Maksimova V., Wikie T., Smith S., Phelps C., Melvin C., Yu L. et al. HTLV-1 Hbz protein, but not hbz mRNA secondary structure, is critical for viral persistence and disease development. PLOS Pathog. 19, e1011459 (2023). doi: 10.1371/journal.ppat.1011459 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Valeri V. W., Hryniewicz A., Andresen V., Jones K., Fenizia C., Bialuk I. et al. Requirement of the human T-cell leukemia virus p12 and p30 products for infectivity of human dendritic cells and macaques but not rabbits. Blood 116, 3809–3817 (2010). doi: 10.1182/blood-2010-05-284141 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Urano E., Ueda K., Higuchi M., Furujawa M., Okamura T., Tanaka Y., et al. Establishment of a Cynomolgus Macaque Model of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Direct Inoculation of Adult T-Cell Leukemia Patient-Derived Cell Lines for HTLV-1 Infection. J. Virol. 96, e01339–22 (2022). doi: 10.1128/jvi.01339-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Gutowska A., McKinnon K., Sarkis S., Doster M. N., Bissa M., Moles R. et al. Transient Viral Activation in Human T Cell Leukemia Virus Type 1-Infected Macaques Treated With Pomalidomide. Front. Med. 9, 897264 (2022). doi: 10.3389/fmed.2022.897264 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Willems L., Kerkhofs P., Dequiedt F., Portetelle D., Mammerickx M., Burny A. et al. Attenuation of bovine leukemia virus by deletion of R3 and G4 open reading frames. Proc. Natl. Acad. Sci. U. S. A. 91, 11532–11536 (1994). doi: 10.1073/pnas.91.24.11532 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Sagata N., Yasunaga T., Tsuzuku-Kawamura J., Ohishi K., Ogawa Y. & Ikawa Y. Complete nucleotide sequence of the genome of bovine leukemia virus: its evolutionary relationship to other retroviruses. Proc. Natl. Acad. Sci. 82, 677–681 (1985). doi: 10.1073/pnas.82.3.677 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Rosewick N., Durkin K. & Van Den Broeke A. Bovine leukemia virus isolate YR2, complete genome. (2015). [Google Scholar]
- 50.Derse D. trans-acting regulation of bovine leukemia virus mRNA processing. J. Virol. 62, 1115–1119 (1988). doi: 10.1128/JVI.62.4.1115-1119.1988 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Rosen C. A., Sodroski J. G., Willems L., Kettmann R., Campbell K., Zaya R. et al. The 3’ region of bovine leukemia virus genome encodes a trans-activator protein. EMBO J. 5, 2585–2589 (1986). doi: 10.1002/j.1460-2075.1986.tb04538.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Durkin K., Rosewick N., Artesi M., Hahaut V., Griebel P., Arsic N. et al. Characterization of novel Bovine Leukemia Virus (BLV) antisense transcripts by deep sequencing reveals constitutive expression in tumors and transcriptional interaction with viral microRNAs. Retrovirology 13, 33 (2016). doi: 10.1186/s12977-016-0267-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Rosewick N., Durkin K., Artesi M., Marçais A., Hahaut V., Griebel P. et al. Cis-perturbation of cancer drivers by the HTLV-1/BLV proviruses is an early determinant of leukemogenesis. Nat. Commun. 8, 15264 (2017). doi: 10.1038/ncomms15264 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Sherwood D. R., Butler J. A., Kramer J. M. & Sternberg P. W. FOS-1 Promotes Basement-Membrane Removal during Anchor-Cell Invasion in C. elegans. Cell 121, 951–962 (2005). doi: 10.1016/j.cell.2005.03.031 [DOI] [PubMed] [Google Scholar]
- 55.Toffoli B., Zennaro C., Winkler C., Giordano Attianese G. M. P., Bernardi S., Carraro M. et al. Hemicentin 1 influences podocyte dynamic changes in glomerular diseases. Am. J. Physiol. Renal Physiol. 314, F1154–F1165 (2018). doi: 10.1152/ajprenal.00198.2017 [DOI] [PubMed] [Google Scholar]
- 56.Chowdhury A., Hasselbach L., Echtermeyer F., Jyotsana N., Theilmeier G. & Herzog C. Fibulin-6 regulates pro-fibrotic TGF-β responses in neonatal mouse ventricular cardiac fibroblasts. Sci. Rep. 7, 42725 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Safari R., Jacques J.-R., Brostaux Y. & Willems L. Ablation of non-coding RNAs affects bovine leukemia virus B lymphocyte proliferation and abrogates oncogenesis. PLoS Pathog. 16, e1008502 (2020). doi: 10.1371/journal.ppat.1008502 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Florins A., Reichert M., Asquith B., Bouzar A.-B., Jean G., François C. et al. Earlier onset of delta-retrovirus-induced leukemia after splenectomy. PloS One 4, e6943 (2009). doi: 10.1371/journal.pone.0006943 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Stone D. M., Norton L. K., Chambers J. C. & Meek W. J. CD4 T Lymphocyte Activation in BLV-Induced Persistent B Lymphocytosis in Cattle. Clin. Immunol. 96, 280–288 (2000). doi: 10.1006/clim.2000.4900 [DOI] [PubMed] [Google Scholar]
- 60.Orlik O. & Splitter G. A. Progression to persistent lymphocytosis and tumor development in bovine leukemia virus (BLV)-infected cattle correlates with impaired proliferation of CD4+ T cells in response to gag- and env-encoded BLV proteins. J. Virol. 70, 7584–7593 (1996). doi: 10.1128/JVI.70.11.7584-7593.1996 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Debacq C., Asquith B., Kerkhofs P., Portetelle D., Burny A., Kettmann R. et al. Increased cell proliferation, but not reduced cell death, induces lymphocytosis in bovine leukemia virus-infected sheep. Proc. Natl. Acad. Sci. 99, 10048–10053 (2002). doi: 10.1073/pnas.142100999 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Asquith B., Zhang Y., Mosley A. J., de Lara C. M., Wallace D. L., Worth A. et al. In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection. Proc. Natl. Acad. Sci. 104, 8035–8040 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Merezak C., Reichert M., Van Lint C., Kerkhofs P., Portetelle D., Willems L. et al. Inhibition of Histone Deacetylases Induces Bovine Leukemia Virus Expression In Vitro and In Vivo. J. Virol. 76, 5034–5042 (2002). doi: 10.1128/jvi.76.10.5034-5042.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Hubaux R., Vandermeers F., Crisanti C., Kapoor V., Burny A., Mascaux C. et al. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. Eur. J. Cancer Oxf. Engl. 1990 46, 1724–1734 (2010). doi: 10.1016/j.ejca.2010.03.021 [DOI] [PubMed] [Google Scholar]
- 65.Takeshima S., Ohno A. & Aida Y. Bovine leukemia virus proviral load is more strongly associated with bovine major histocompatibility complex class II DRB3 polymorphism than with DQA1 polymorphism in Holstein cow in Japan. Retrovirology 16, 14 (2019). doi: 10.1186/s12977-019-0476-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Nakatsuchi A., Matsumoto Y. & Aida Y. Influence of BoLA-DRB3 Polymorphism and Bovine Leukemia Virus (BLV) Infection on Dairy Cattle Productivity. Vet. Sci. 10, 250 (2023). doi: 10.3390/vetsci10040250 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Martella C., Tollenaere A. I., Waast L., Lacombe B., Groussaud D., Margottin-Goguet F. et al. Human T-Cell Lymphotropic Virus Type 1 Transactivator Tax Exploits the XPB Subunit of TFIIH during Viral Transcription. J. Virol. 94, e02171–19 (2020). doi: 10.1128/JVI.02171-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Ernzen K., Melvin C., Yu L., Phelps C., Niewiesk S., Green P. L. et al. The PRMT5 inhibitor EPZ015666 is effective against HTLV-1-transformed T-cell lines in vitro and in vivo. Front. Microbiol. 14, 1101544 (2023). doi: 10.3389/fmicb.2023.1101544 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Belrose G., Gross A., Olindo S., Lézin A., Dueymes M., Komla-Soukha I. et al. Effects of valproate on Tax and HBZ expression in HTLV-1 and HAM/TSP T lymphocytes. Blood 118, 2483–2491 (2011). doi: 10.1182/blood-2010-11-321364 [DOI] [PubMed] [Google Scholar]
- 70.Lezin A., Gillet N., Olindo S., Signaté A., Grandvaux N., Verlaeen O. et al. Histone deacetylase–mediated transcriptional activation reduces proviral loads in HTLV-1–associated myelopathy/tropical spastic paraparesis patients. Blood 110, 3722–3728 (2007). doi: 10.1182/blood-2007-04-085076 [DOI] [PubMed] [Google Scholar]
- 71.Willems L., Kettmann R., Dequiedt F., Portetelle D., Vonèche V., Cornil I. et al. In vivo infection of sheep by bovine leukemia virus mutants. J. Virol. 67, 4078–4085 (1993). doi: 10.1128/JVI.67.7.4078-4085.1993 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Arpin-André C., Laverdure S., Barbeau B., Gross A. & Mesnard J.-M. Construction of a reporter vector for analysis of bidirectional transcriptional activity of retrovirus LTR. Plasmid 74, 45–51 (2014). doi: 10.1016/j.plasmid.2014.06.001 [DOI] [PubMed] [Google Scholar]
- 73.Derse D. & Casey J. W. Two elements in the bovine leukemia virus long terminal repeat that regulate gene expression. Science 231, 1437–1440 (1986). doi: 10.1126/science.3006241 [DOI] [PubMed] [Google Scholar]
- 74.Piccinini F., Kiss A. & Horvath P. CellTracker (not only) for dummies. Bioinformatics 32, 955–957 (2016). doi: 10.1093/bioinformatics/btv686 [DOI] [PubMed] [Google Scholar]
- 75.Lew A. E., Bock R. E., Miles J., Cuttell L. B., Steer P. & Nadin-Davis S. A. Sensitive and specific detection of bovine immunodeficiency virus and bovine syncytial virus by 5′ Taq nuclease assays with fluorescent 3′ minor groove binder-DNA probes. J. Virol. Methods 116, 1–9 (2004). doi: 10.1016/j.jviromet.2003.10.006 [DOI] [PubMed] [Google Scholar]
- 76.Bankhead P., Loughrey M. B., Fernández J. A., Dombrowski Y., McArt D. G., Dunne P. D. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017). doi: 10.1038/s41598-017-17204-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Kerkhofs P., Adam E., Droogmans L., Portetelle D., Mammerickx M., Burny A. et al. Cellular pathways involved in the ex vivo expression of bovine leukemia virus. J. Virol. 70, 2170–2177 (1996). doi: 10.1128/JVI.70.4.2170-2177.1996 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Livak K. J. & Schmittgen T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif 25, 402–408 (2001). doi: 10.1006/meth.2001.1262 [DOI] [PubMed] [Google Scholar]